Health Economics›Bladder cancer›Adjuvant therapy

Adjuvant therapy

Bladder cancer · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	—	—	—	—	1
PGC Variant #01	—	R 3 886	21d	—	~15.8 mo	—	—	1
MVEC Variant #01	—	R 1 774	28d	49.7 mo	—	55	R 97 585 PFS proxy	1
MCV Variant #01	—	R 795	28d	—	~44.0 mo	—	—	1
Cisplatin and Methotrexate Variant #01	—	R 353	21d	43.4 mo	—	63	R 22 227 PFS proxy	1
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	72.3 mo	—	—	2

6 of 6 regimens shown